Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland
Objectives: We aimed to describe mesothelin (MSLN) and programmed cell death 1 ligand 1 (PD-L1) tumour overexpression amongst patients with malignant mesothelioma (MM), and their associations with survival, amongst a cohort of patients with MM in Finland. Methods: Between 2004 and 2017, 91 adults wi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294220300952 |
| _version_ | 1818871909346967552 |
|---|---|
| author | David Vizcaya Bahman Farahmand Annette O. Walter Christoph Kneip Korinna Jöhrens Mikko Tukiainen Arndt A. Schmitz |
| author_facet | David Vizcaya Bahman Farahmand Annette O. Walter Christoph Kneip Korinna Jöhrens Mikko Tukiainen Arndt A. Schmitz |
| author_sort | David Vizcaya |
| collection | DOAJ |
| description | Objectives: We aimed to describe mesothelin (MSLN) and programmed cell death 1 ligand 1 (PD-L1) tumour overexpression amongst patients with malignant mesothelioma (MM), and their associations with survival, amongst a cohort of patients with MM in Finland. Methods: Between 2004 and 2017, 91 adults with histologically confirmed MM were identified from the Auria Biobank in Finland and followed-up using linked data from electronic health records and national statistics. Biomarker content in tumour cell membranes was determined using automated Immunohistochemistry on histological sections. Stained tumour sections were scored for MSLN and PD-L1 intensity. Adjusted associations between MSLN/PD-L1 co-expression and mortality were evaluated by estimating hazard ratios (HRs) with 95% confidence intervals (CIs) using Cox regression. Results: Biomarker overexpression occurred in 52 patients for MSLN and 34 patients for PD-L1 and was associated with tumour histology and certain comorbidities. Fifteen per cent of patients had a tumour that overexpressed both biomarkers; r =-0.244, p-value: 0.02. Compared with MSLN+/PD-L1+ patients, HRs (95% CIs) for death were 4.18 (1.71–10.23) for MSLN-/PD-L1+ patients, 3.03 (1.35–6.77) for MSLN-/PD-L1- patients, and 2.13 (0.97–4.67) for MSLN+/PD-L1- patients. Conclusions: Both MSLN and PD-L1 markers were independent prognostic indicators in patients with MM. Overexpression of MSLN was associated with longer survival; yet their combined expression gave a better indication of survival. The risk of death was four times higher amongst MSLN-/PD-L1+ patients than in MSLN+/PD-L1+ patients. |
| first_indexed | 2024-12-19T12:30:24Z |
| format | Article |
| id | doaj.art-fd3e169f9bff476293193501e828ad3d |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-19T12:30:24Z |
| publishDate | 2020-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-fd3e169f9bff476293193501e828ad3d2022-12-21T20:21:24ZengElsevierCancer Treatment and Research Communications2468-29422020-01-0125100260Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in FinlandDavid Vizcaya0Bahman Farahmand1Annette O. Walter2Christoph Kneip3Korinna Jöhrens4Mikko Tukiainen5Arndt A. Schmitz6Bayer Pharmaceuticals, Sant Joan Despí, Spain; Corresponding author.Epidemiology, Bayer AB, Stockholm, SwedenBayer AG, Berlin, GermanyBayer AG, Berlin, GermanyInstitute of Pathology University Hospital Carl Gustav Carus, Dresden, Germany; Provitro AG, Berlin, GermanyAuria Biobank, University of Turku and Turku University Hospital, Turku, FinlandBayer AG, Berlin, GermanyObjectives: We aimed to describe mesothelin (MSLN) and programmed cell death 1 ligand 1 (PD-L1) tumour overexpression amongst patients with malignant mesothelioma (MM), and their associations with survival, amongst a cohort of patients with MM in Finland. Methods: Between 2004 and 2017, 91 adults with histologically confirmed MM were identified from the Auria Biobank in Finland and followed-up using linked data from electronic health records and national statistics. Biomarker content in tumour cell membranes was determined using automated Immunohistochemistry on histological sections. Stained tumour sections were scored for MSLN and PD-L1 intensity. Adjusted associations between MSLN/PD-L1 co-expression and mortality were evaluated by estimating hazard ratios (HRs) with 95% confidence intervals (CIs) using Cox regression. Results: Biomarker overexpression occurred in 52 patients for MSLN and 34 patients for PD-L1 and was associated with tumour histology and certain comorbidities. Fifteen per cent of patients had a tumour that overexpressed both biomarkers; r =-0.244, p-value: 0.02. Compared with MSLN+/PD-L1+ patients, HRs (95% CIs) for death were 4.18 (1.71–10.23) for MSLN-/PD-L1+ patients, 3.03 (1.35–6.77) for MSLN-/PD-L1- patients, and 2.13 (0.97–4.67) for MSLN+/PD-L1- patients. Conclusions: Both MSLN and PD-L1 markers were independent prognostic indicators in patients with MM. Overexpression of MSLN was associated with longer survival; yet their combined expression gave a better indication of survival. The risk of death was four times higher amongst MSLN-/PD-L1+ patients than in MSLN+/PD-L1+ patients.http://www.sciencedirect.com/science/article/pii/S2468294220300952MesotheliomaPrognosisBiomarkersDisease progressionProgrammed cell death 1 ligand 1 |
| spellingShingle | David Vizcaya Bahman Farahmand Annette O. Walter Christoph Kneip Korinna Jöhrens Mikko Tukiainen Arndt A. Schmitz Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland Cancer Treatment and Research Communications Mesothelioma Prognosis Biomarkers Disease progression Programmed cell death 1 ligand 1 |
| title | Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland |
| title_full | Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland |
| title_fullStr | Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland |
| title_full_unstemmed | Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland |
| title_short | Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland |
| title_sort | prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in finland |
| topic | Mesothelioma Prognosis Biomarkers Disease progression Programmed cell death 1 ligand 1 |
| url | http://www.sciencedirect.com/science/article/pii/S2468294220300952 |
| work_keys_str_mv | AT davidvizcaya prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT bahmanfarahmand prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT annetteowalter prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT christophkneip prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT korinnajohrens prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT mikkotukiainen prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland AT arndtaschmitz prognosisofpatientswithmalignantmesotheliomabyexpressionofprogrammedcelldeath1ligand1andmesothelininacontemporarycohortinfinland |